View More View Less
  • 1 Magyar Honvédség Egészségügyi Központ, Fül-Orr-Gégészeti és Fej-Nyaksebészeti Osztály, Budapest, Róbert Károly krt. 44., 1134
  • | 2 Jahn Ferenc Dél-pesti Kórház, Fül-Orr-Gégészeti és Fej-Nyaksebészeti Osztály, Budapest
  • | 3 Budapesti Corvinus Egyetem, Egészségügyi Közgazdaságtan Tanszék, Budapest
  • | 4 Jahn Ferenc Dél-pesti Kórház, Urológiai Osztály, Budapest
  • | 5 Szent Imre Kórház, Sebészeti Osztály, Budapest
  • | 6 Semmelweis Egyetem, Általános Orostudományi Kar, I. Sebészeti Klinika, Budapest
Open access

Összefoglaló. Bevezetés: Régóta ismert, hogy a daganatokhoz társuló emelkedett vérlemezkeszám rosszabb túléléssel társul. Fej-nyak tumoros betegek esetében kevés információ áll rendelkezésünkre ezzel az összefüggéssel kapcsolatban. Célkitűzés: Vizsgálatunk célja a fej-nyak daganatos betegek prognózisa és a thrombocytosis közötti összefüggés tanulmányozása volt. Módszer: Különféle stádiumú és lokalizációjú, 312, fej-nyak tumoros beteg retrospektív adatait elemeztük. A műtét előtti vérlemezkeszámokat vizsgáltuk, a 300 G/l feletti értéket tekintettük emelkedett thrombocytaszámnak. A vérlemezkeszám és a túlélés közötti kapcsolatot Kaplan–Meier-módszerrel és multivariáns Cox-regresszióval elemeztük. Eredmények: Emelkedett thrombocytaszám mellett szignifikánsan rosszabb túlélést észleltünk (5 éves túlélés: p = 0,007, betegségmentes túlélés: p = 0,192). Ez az összefüggés még akkor is fennállt, amikor multivariáns analízissel nemre, korra, stádiumra, differenciáltsági fokra, lokalizációra, valamint fehér- és vörösvérsejtszámra korrigáltuk az elemzést (5 éves túlélés: p = 0,027). A különféle anatómiai lokalizációkban eltérő mértékben észleltünk 300 G/l feletti vérlemezkeszámot (algarat: 43,6%, sub- és supraglottis: 35,8%, szájüreg: 35,7%, hangszalag: 22,5%, szájgarat: 19%, multiplex: 50%), ez azonban nem befolyásolta szignifikánsan a túlélést (p = 0,603). Következtetés: A daganathoz társuló thrombocytosis összefüggésbe hozható a fej-nyak tumoros betegek rosszabb túlélésével. Az egyes lokalizációkban talált különböző vérlemezkeszámok nem befolyásolják eltérő mértékben a túlélést. Orv Hetil. 2021; 162(17): 676–682.

Summary. Introduction: The association between cancer-related thrombocytosis and worse survival has been described with a variety of solid neoplasms. However, only limited data are available on the prognostic significance of elevated platelet count in head and neck tumours. Objective: We aimed to investigate the correlation between the survival of patients with head and neck cancer and thrombocytosis. Method: We conducted an analysis of the data from 312 patients with head and neck squamous cell carcinoma of various stages and locations. Preoperative platelet counts were analysed; elevated platelet count was defined as 300 G/l or higher. The influence of platelet count on survival was calculated with the Kaplan–Meier method as well as with multivariate Cox regression. Results: In patients with excessive thrombocytosis, survival was significantly worse (overall survival: p = 0.007, disease-free survival: p = 0.192). This association remained significant even after adjusting the multivariate analysis for age, gender as well as tumour stage, grade, location, red and white blood cell count (overall survival: p = 0.027). The magnitude of thrombocytosis differed among tumours of different anatomical locations (hypopharynx: 43.6%, sub- and supraglottis: 35.8%, oral cavity: 35.7%, vocal cord: 22.5%, oropharynx: 19%, multiple: 50%), but this did not affect survival significantly (p = 0.603). Conclusion: Elevated platelet count may be related to a worse prognosis in head and neck squamous cell carcinoma patients. The impact of thrombocytosis does not vary with the anatomical location of the tumour. Orv Hetil. 2021; 162(17): 676–682.

  • 1

    Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68: 394–424. [Erratum: CA Cancer J Clin. 2020; 70: 313.]

  • 2

    Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359–E386.

  • 3

    Wang L, YeErDaoLaiTi Y, Yang G, et al. Effects of regional and general anesthesia on survival in head and neck cancer. Int J Pharmacol. 2018; 14: 528–533.

  • 4

    He Y, Xia T, Bian H, et al. Pretreatment thrombocytosis predicts survival in colorectal cancer. Clin Res Hepatol Gastroenterol. 2016; 40: e59–e60.

  • 5

    Baranyai Zs, Jósa V, Tóth A, et al. Paraneoplastic thrombocytosis in gastrointestinal cancer. Platelets 2016; 27: 269–275.

  • 6

    Josa V, Krzystanek M, Eklund AC, et al. Relationship of postoperative thrombocytosis and survival of patients with colorectal cancer. Int J Surg. 2015; 18: 1–6.

  • 7

    Jósa V, Krzystanek M, Vass T, et al. Thrombocytosis of liver metastasis from colorectal cancer as predictive factor. Pathol Oncol Res. 2015; 21: 991–997.

  • 8

    Hu C, Chen R, Chen W, et al. Thrombocytosis is a significant indictor of hypercoagulability, prognosis and recurrence in gastric cancer. Exp Ther Med. 2014; 8: 125–132.

  • 9

    Li FX, Wei LJ, Zhang H, et al. Significance of thrombocytosis in clinicopathologic characteristics and prognosis of gastric cancer. Asian Pac J Cancer Prev. 2014; 15: 6511–6517.

  • 10

    Cheng J, Zeng Z, Ye Q, et al. The association of pretreatment thrombocytosis with prognosis and clinicopathological significance in cervical cancer: a systematic review and meta-analysis. Oncotarget 2017; 8: 24327–24336.

  • 11

    Cozzi GD, Samuel JM, Fromal JT, et al. Thresholds and timing of pre-operative thrombocytosis and ovarian cancer survival: analysis of laboratory measures from electronic medical records. BMC Cancer 2016; 16: 612.

  • 12

    Feng Z, Wen H, Bi R, et al. Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients. BMC Cancer 2016; 16: 43.

  • 13

    Barber EL, Boggess JF, Van Le L, et al. Preoperative thrombocytosis and leukocytosis among ovarian cancer patients are associated with postoperative death. Gynecol Oncol. 2015; 137: 43.

  • 14

    Chadha AS, Kocak-Uzel E, Das P, et al. Paraneoplastic thrombocytosis independently predicts poor prognosis in patients with locally advanced pancreatic cancer. Acta Oncol. 2015; 54: 971–978.

  • 15

    Kocak E, Das P, Delclos M, et al. Paraneoplastic thrombocytosis is a significant independent prognostic factor for overall and progression free survival in locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2014; 90: S365.

  • 16

    Kim M, Chang H, Yang HC, et al. Preoperative thrombocytosis is a significant unfavorable prognostic factor for patients with resectable non-small cell lung cancer. World J Surg Oncol. 2014; 12: 37.

  • 17

    Wang J, Luo M, Wu H, et al. Preoperative thrombocytosis as a predictor of unfavorable survival in resectable non-small cell lung cancer. J Clin Oncol. 2013; 31(15 Suppl): e18531.

  • 18

    Maráz A, Furák J, Varga Z, et al. Thrombocytosis has a negative prognostic value in lung cancer. Anticancer Res. 2013; 33: 1725–1729.

  • 19

    Rajkumar A, Szallasi A. Paraneoplastic thrombocytosis in breast cancer. Anticancer Res. 2013; 33: 4545–4546.

  • 20

    Lu CC, Chang KW, Chou FC, et al. Association of pretreatment thrombocytosis with disease progression and survival in oral squamous cell carcinoma. Oral Oncol. 2007; 43: 283–288.

  • 21

    Takenaka Y, Oya R, Kitamiura T, et al. Platelet count and platelet-lymphocyte ratio as prognostic markers for head and neck squamous cell carcinoma: meta-analysis. Head Neck 2018; 40: 2714–2723.

  • 22

    Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994; 81: 515–526.

  • 23

    StataCorp. Statistical Software: Release 14. StataCorp LP, College Station, TX, 2015.

  • 24

    Buergy D, Wenz F, Groden C, et al. Tumor-platelet interaction in solid tumors. Int J Cancer 2012; 130: 2747–2760.

  • 25

    Sierko E, Wojtukiewicz MZ. Inhibition of platelet function: does it offer a chance of better cancer progression control? Semin Thromb Hemost. 2007; 33: 712–721.

  • 26

    Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer 2011; 11: 123–134.

  • 27

    Nieswandt B, Hafner M, Echtenacher B, et al. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res. 1999; 59: 1295–1300.

  • 28

    Palumbo JS, Talmage KE, Massari JV, et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 2005; 105: 178–185.

  • 29

    Placke T, Kopp HG, Salih HR. Modulation of natural killer cell anti-tumor reactivity by platelets. J Innate Immun. 2011; 3: 374–382.

  • 30

    Erpenbeck L, Schön MP. Deadly allies: the fatal interplay between platelets and metastasizing cancer cells. Blood 2010; 115: 3427–3436.

  • 31

    Stone RL, Nick AM, McNeish IA, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012; 366: 610–618.

  • 32

    Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004; 40: 2293–2306.

  • 33

    Birgegård G, Aapro MS, Bokemeyer C, et al. Cancer-related anemia: pathogenesis, prevalence and treatment. Oncology 2005; 68(Suppl 1): 3–11.

  • 34

    Chen MH, Chang PM, Chen PM, et al. Prognostic significance of a pretreatment hematologic profile in patients with head and neck cancer. J Cancer Res Clin Oncol. 2009; 135: 1783–1790.

  • 35

    Gao J, Zhang HY, Xia YF. Increased platelet count is an indicator of metastasis in patients with nasopharyngeal carcinoma. Tumour Biol. 2013; 34: 39–45.

  • 36

    Rachidi S, Wallace K, Day TA, et al. Lower circulating platelet counts and antiplatelet therapy independently predict better outcomes in patients with head and neck squamous cell carcinoma. J Hematol Oncol. 2014; 7: 65.

  • 37

    Shoultz-Henley S, Garden AS, Mohamed AS, et al. Prognostic value of pretherapy platelet elevation in oropharyngeal cancer patients treated with chemoradiation. Int J Cancer 2016; 138: 1290–1297.

  • 38

    Pardo L, Valero C, López M, et al. The prognostic value of pretreatment platelet count in patients with head and neck squamous cell carcinoma. Auris Nasus Larynx 2017; 44: 313–318.

  • 39

    Chen YP, Chen C, Mai ZY, et al. Pretreatment platelet count as a predictor for survival and distant metastasis in nasopharyngeal carcinoma patients. Oncol Lett. 2015; 9: 1458–1466.

  • 40

    Lin CY, Kwon H, Rangel Rivera GO, et al. Sex differences in using systemic inflammatory markers to prognosticate patients with head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2018; 27: 1176–1185.

  • 41

    Eidelman O, Jozwik C, Huang W, et al. Gender dependence for a subset of the low-abundance signaling proteome in human platelets. Hum Genomics Proteomics 2010; 2010: 164906.

  • 42

    Drabsch Y, ten Dijke P. TGF-β signalling and its role in cancer progression and metastasis. Cancer Metastasis Rev. 2012; 31: 553–568.

  • 43

    Chen WJ, Jin W, Hardegen N, et al. Conversion of peripheral CD4+CD25 naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3. J Exp Med. 2003; 198: 1875–1886.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 122 122 94
PDF Downloads 73 73 40